Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
AstraZeneca
Express Scripts
Baxter
Moodys

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR NITAZOXANIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nitazoxanide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001081 ↗ A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To determine the frequency of complete, marked, and partial clinical responses in patients with cryptosporidiosis treated with 6 weeks of NTZ versus 21 days of placebo. To determine the safety of NTZ in subjects with cryptosporidiosis. There is no proven therapy for cryptosporidiosis in persons with AIDS. Nitazoxanide appears to be a good candidate drug for further evaluation because of its effectiveness in preclinical models, the data from early clinical trials and its safety profile. Cooperation between clinical researchers and basic scientists in clinical trials of agents for HIV infection and its complications is a high priority for the ACTG, the NIAID, and the NIH. Thus, it is important to design a clinical trial of NTZ that includes cooperation with basic scientists.
NCT00002158 ↗ A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis Unknown status Romark Laboratories L.C. N/A 1969-12-31 The purpose of this study is to see if nitazoxanide (NTZ) can be used to treat AIDS patients suffering from cryptosporidiosis (diarrhea caused by the parasite Cryptosporidium).
NCT00002444 ↗ A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea Completed Unimed Pharmaceuticals Phase 1 1995-10-01 To determine the pharmacokinetics profile of single doses of nitazoxanide (NTZ) in patients with AIDS-related cryptosporidial diarrhea. To determine steady state concentrations of NTZ following repeated dosing. To assess the safety and efficacy of 4 dose levels of NTZ in these patients. Cryptosporidial enterocolitis in AIDS patients is frequently chronic and severe, contributing substantially to morbidity, mortality, and health care costs in this population. NTZ exhibits antimicrobial activity that may extend to Cryptosporidial infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nitazoxanide

Condition Name

Condition Name for Nitazoxanide
Intervention Trials
Covid19 13
COVID-19 11
Chronic Hepatitis C 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nitazoxanide
Intervention Trials
COVID-19 24
Hepatitis 14
Hepatitis C 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nitazoxanide

Trials by Country

Trials by Country for Nitazoxanide
Location Trials
United States 177
Egypt 26
Australia 11
South Africa 7
Brazil 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nitazoxanide
Location Trials
Florida 16
New York 15
Texas 12
California 10
Georgia 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nitazoxanide

Clinical Trial Phase

Clinical Trial Phase for Nitazoxanide
Clinical Trial Phase Trials
Phase 4 10
Phase 3 24
Phase 2/Phase 3 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nitazoxanide
Clinical Trial Phase Trials
Completed 43
Recruiting 19
Not yet recruiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nitazoxanide

Sponsor Name

Sponsor Name for Nitazoxanide
Sponsor Trials
Romark Laboratories L.C. 29
Tanta University 9
National Institute of Allergy and Infectious Diseases (NIAID) 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nitazoxanide
Sponsor Trials
Other 133
Industry 48
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Moodys
AstraZeneca
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.